A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.1111/dom.14010
Abstract: To report the first study of temelimab, a monoclonal antibody neutralizing the pathogenic human endogenous retrovirus type W envelope, in patients with type 1 diabetes (T1D). read more here.
Keywords: type envelope; study temelimab; human endogenous; retrovirus type ... See more keywords